DRG Market Assessment reports

The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson…

Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…

The treatment of adult psoriasis represents an increasingly lucrative market for nonconventional systemic therapies, particularly for moderate to severe cases where conventional systemic and…

MARKET OUTLOOK The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen),…

Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…

The psoriasis therapy market has become increasingly lucrative due to the growing use of targeted agents. The newer IL-17 and IL-23 inhibitors (e.g., Eli Lilly’s Taltz, Johnson & Johnson…

The psoriasis treatment landscape has significantly evolved in the past few years. A plethora of psoriasis treatments are available in the EU5, ranging from topical agents to conventional systemic…

With a drug-treated population of more than 3.3 million in the United States, France, Germany, and the United Kingdom, the moderate to severe psoriasis therapy market has been a lucrative space for…

Psoriasis affects pediatric, adolescent, and adult patients similarly; however, the effective management of pediatric psoriasis is more challenging owing to the limited number of treatments…

The treatment of adult psoriasis represents an increasingly lucrative market for nonconventional systemic therapies in the moderate to severe space, for which conventional systemic and topical…

Clarivate Epidemiology’s coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PsO for each country, as…

Clarivate Epidemiology’s coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PsO for each country, as…